Icosapent ethyl for hypertriglyceridaemia and atherosclerosis: greater RESPECT for increased therapeutic use.

The article discusses the use of icosapent ethyl (IPE) for the treatment of hypertriglyceridemia and atherosclerosis. Hypertriglyceridemia is a significant risk factor for cardiovascular disease, and various medications have been developed to target elevated triglyceride levels. IPE, a highly purified omega-3 fatty acid, has shown promise in reducing adverse cardiovascular events. Three major clinical trials have demonstrated the clinical benefits of IPE, including a reduction in major coronary events and cardiovascular mortality. Despite some concerns about side effects and cost, the evidence supports the use of IPE in appropriate patients. [Extracted from the article]